Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia

Cited by (1,049)

Items 101–200 of 1,049

1. Genomewide association for schizophrenia in the CATIE study: results of stage 1
   Patrick F. Sullivan, Danyu Y. Lin, Jung‐Ying Tzeng, Edwin J. C. G. van den Oord, Diana O. Perkins, T. Scott Stroup, Michael J. Wagner, Seonjoo Lee, Fred A. Wright, Fei Zou et al. · 2008 · Molecular Psychiatry
2. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
   Maria Jesús Arranz, José de León · 2007 · Molecular Psychiatry
3. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia
   Lodge, Daniel J., Grace, Anthony A. · 2011 · Trends in Pharmacological Sciences
4. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania
   Heinz Grunze, Eduard Vieta, Guy M. Goodwin, Charles L. Bowden, Rasmus Wentzer Licht, Hans‐Jürgen Möller, Siegfried F. Kasper, WFSBP Task Force on Treatment Guide · 2009 · The World Journal of Biological Psychiatry
5. Recovery Model of Mental Illness: A Complementary Approach to Psychiatric Care
   KS Jacob · 2015 · Indian Journal of Psychological Medicine
6. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis
   Jianping Zhang, Juan A. Gallego, Delbert G. Robinson, Anil K. Malhotra, John Michael Kane, Christoph Ulrich Correll · 2012 · The International Journal of Neuropsychopharmacology
7. Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009
   Juan A. Gallego, John Bonetti, Jianping Zhang, John Michael Kane, Christoph Ulrich Correll · 2012 · Schizophrenia Research
8. Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
   Nevena Divac, Milica S. Prostran, Igor Jakovčevski, Nataša Cerovac · 2014 · BioMed Research International
9. Dementia and cognitive impairment in ESRD: diagnostic and therapeutic strategies
   Manjula Kurella Tamura, Kristine S. Yaffe · 2010 · Kidney International
10. Treatment-Resistant Schizophrenia
    Hélio Elkis · 2007 · Psychiatric Clinics of North America
11. Alzheimer's Disease and Mild Cognitive Impairment
    Brendan J. Kelley, Ronald Carl Petersen · 2007 · Neurologic Clinics
12. Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method
    Stefan Leucht, Myrto T. Samara, Stephan Heres, Maxine X. Patel, Toshi A. Furukawa, Andrea Cipriani, John Richard Geddes, John M. Davis · 2015 · Schizophrenia Bulletin
13. Efficacy of Music Therapy in the Treatment of Behavioral and Psychiatric Symptoms of Dementia
    Raglio, Alfredo, Bellelli, Giuseppe, Traficante, Daniela, Gianotti, Marta, Ubezio, Maria Chiara, Villani, Daniele, Trabucchi, Marco · 2008 · Alzheimer Disease & Associated Disorders
14. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia
    DiBonaventura, Marco, Gabriel, Susan, Dupclay, Leon, Gupta, Shaloo, Kim, Edward · 2012 · BMC Psychiatry
15. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia
    Peter Falkai, Thomas Wobrock, Jeffrey Alan Lieberman, Birte Yding Glenthoj, Wagner F. Gattaz, Hans‐Jürgen Möller, WFSBP Task Force on Treatment Guide · 2006 · The World Journal of Biological Psychiatry
16. Sowing the seeds of doubt: a narrative review on metacognitive training in schizophrenia
    Moritz, Steffen, Andreou, Christina, Schneider, Brooke C., Wittekind, Charlotte E., Menon, Mahesh, Balzan, Ryan P., Woodward, Todd S. · 2014 · Clinical Psychology Review
17. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement
    Juszczak, Edmund, Altman, Douglas G., Hopewell, Sally, Schulz, Kenneth · 2019 · JAMA
18. Pathophysiologically based treatment interventions in schizophrenia
    David A. Lewis, Guillermo González‐Burgos · 2006 · Nature Medicine
19. Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST)
    Michael Davidson, Silvana Galderisi, Mark Weiser, Nomi Werbeloff, Wolfgang Fleischhacker, Richard S.E. Keefe, Han Boter, Ireneus P.M. Keet, Dan Prelipceanu, JANUSZ K. RYBAKOWSKI et al. · 2009 · American Journal of Psychiatry
20. Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer’s Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness Trial
    Sultzer, David L., Davis, Sonia M., Tariot, Pierre N., Dagerman, Karen S., Lebowitz, Barry D., Lyketsos, Constantine G., Rosenheck, Robert A., Hsiao, John K., Lieberman, Jeffrey A., Schneider, Lon S. et al. · 2008 · American Journal of Psychiatry
21. Cure therapeutics and strategic prevention: raising the bar for mental health research
    Thomas R. Insel, Edward M. Scolnick · 2005 · Molecular Psychiatry
22. Impaired glucose tolerance in first‐episode drug‐naïve patients with schizophrenia
    Leona Spelman, Patricia Walsh, Neda Sharifi, Patrick B Collins, Jogin H. Thakore · 2007 · Diabetic Medicine
23. Schizophrenia
    Marco Picchioni, Robin M. Murray · 2007 · BMJ
24. The metabolic effects of antipsychotic medications
    Newcomer, John W, Haupt, Dan W · 2006 · The Canadian Journal of Psychiatry
25. Antipsychotic drugs and obesity
    Christoph Ulrich Correll, Todd Lencz, Anil K. Malhotra · 2010 · Trends in Molecular Medicine
26. Collaborative care for bipolar disorder, Part II: impact on clinical outcome, function, and costs.
    Bauer, Mark S., McBride, Linda, Williford, William O., Glick, Henry, Kinosian, Bruce, Altshuler, Lori, Beresford, Thomas, Kilbourne, Amy M., Sajatovic, Martha · 2006 · Psychiatric Services
27. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs
    Fribourg, Miguel, Moreno, José L., Holloway, Terrell, Provasi, Davide, Baki, Lia, Mahajan, Rahul, Park, Gyu, Adney, Scott K., Hatcher, Candice, Eltit, José M. et al. · 2011 · Cell
28. Dietary intake of people with severe mental illness: systematic review and meta-analysis
    Scott B. Teasdale, Philip B. Ward, Katherine Samaras, Joseph Firth, Brendon Stubbs, Elise Tripodi, Tracy L. Burrows · 2019 · The British Journal of Psychiatry
29. A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
    Kenneth S. Koblan, JUSTINE M. KENT, Seth C. Hopkins, John Harrison Krystal, Hailong Cheng, ROBERT S. GOLDMAN, Antony D Loebel · 2020 · New England Journal of Medicine
30. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia
    Gunnar Morken, Jan H. Widen, Rolf Wilhelm Gråwe · 2008 · BMC Psychiatry
31. Dropout From Outpatient Mental Health Care in the United States
    Olfson, Mark, Mojtabai, Ramin, Sampson, Nancy A., Hwang, Irving, Druss, Benjamin, Wang, Philip S., Wells, Kenneth B., Pincus, Harold Alan, Kessler, Ronald C. · 2009 · Psychiatric Services
32. The NMDA Receptor and Schizophrenia
    Darrick T. Balu · 2016 · Advances in pharmacology
33. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management
    Peter Manu, Lorena Dima, Matisyahu Shulman, Davy Vancampfort, M.A.F. De Hert, Christoph Ulrich Correll · 2015 · Acta Psychiatrica Scandinavica
34. Medication Adherence: A Review of the Literature and Implications for Clinical Practice
    Julius, Rose J., Novitsky, Mark A., Dubin, William R. · 2009 · Journal of Psychiatric Practice
35. The effect of clinician-patient alliance and communication on treatment adherence in mental health care: a systematic review
    Laura R. Thompson, Rose McCabe · 2012 · BMC Psychiatry
36. Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study
    Marvin S. Swartz, Diana O. Perkins, T. Scott Stroup, Sonia Thomas, George A. Capuano, Robert Alan Rosenheck, Fred W. Reimherr, Mark McGee, Richard S.E. Keefe, Joseph P. McEvoy et al. · 2007 · American Journal of Psychiatry
37. Clinical Guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19
    José de León, Scott C. Armstrong, Kelly L. Cozza · 2005 · Psychosomatics
38. Towards a muscarinic hypothesis of schizophrenia
    Thomas J. Raedler, Frank P. Bymaster, Rajiv Tandon, David Copolov, Brian Dean · 2006 · Molecular Psychiatry
39. Caregiver Burden in Alzheimer Disease: Cross-Sectional and Longitudinal Patient Correlates
    Somaia Mohamed, Robert Alan Rosenheck, Constantine George Lyketsos, Lon S. S. Schneider · 2010 · American Journal of Geriatric Psychiatry
40. Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial☆
    John Michael Kane, F. Cañas, Michelle L. Kramer, L. Ford, Cristiana Gassmann-Mayer, Pilar Lim, Mariëlle Eerdekens · 2006 · Schizophrenia Research
41. Cognitive-behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: Randomised controlled trial
    Garety, Philippa A., Fowler, David G., Freeman, Daniel, Bebbington, Paul, Dunn, Graham, Kuipers, Elizabeth · 2008 · British Journal of Psychiatry
42. Metabolomics: A Global Biochemical Approach to the Study of Central Nervous System Diseases
    Rima Kaddurah‐Daouk, Kousik Krishnan · 2008 · Neuropsychopharmacology
43. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
    Gretchen L. Snyder, Kimberly E. Vanover, Hongwen Zhu, Diane Bemis Miller, James Patrick O'Callaghan, John Tomesch, Peng Li, Qiang Zhang, Vaishnav Krishnan, Joseph P. Hendrick et al. · 2014 · Psychopharmacology
44. Delusional Infestation
    Roland W. Freudenmann, Peter Lepping · 2009 · Clinical Microbiology Reviews
45. Tardive dyskinesia and new antipsychotics
    Christoph Ulrich Correll, Eva M Schenk · 2008 · Current Opinion in Internal Medicine
46. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia
    Rajiv Tandon, Robert H. Belmaker, Wagner F. Gattaz, Juan J López-Ibor, Ahmed Okasha, BRUCE S. SINGH, Dan Joseph Stein, Jean‐Pierre Olié, Wolfgang W. Fleischhacker, Hans‐Juergen Moeller · 2008 · Schizophrenia Research
47. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1
    Jonathan M. Meyer, Vicki Grey Davis, DONALD C. GOFF, Joseph P. McEvoy, Henry A. Nasrallah, Sonia Thomas, Robert Alan Rosenheck, Gail L. Daumit, John Hsiao, Marvin S. Swartz et al. · 2008 · Schizophrenia Research
48. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial
    Lenze, Eric J, Mulsant, Benoit H, Blumberger, Daniel M, Karp, Jordan F, Newcomer, John W, Anderson, Stewart J, Dew, Mary Amanda, Butters, Meryl A, Stack, Jacqueline A, Begley, Amy E et al. · 2015 · The Lancet
49. The history of clozapine and its emergence in the US market
    John F. Crilly · 2007 · History of Psychiatry
50. Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia
    Robert Alan Rosenheck, DOUGLAS L. LESLIE, Jody L. Sindelar, Edward Alan Miller, Haiqun Lin, T. Scott Stroup, Joseph M. McEvoy, Sonia Thomas, Richard S.E. Keefe, Marvin S. Swartz et al. · 2006 · American Journal of Psychiatry
51. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity
    Mitsumasa Kurita, Terrell D. Holloway, Aintzane García‐Bea, Alexey Kozlenkov, Allyson K. Friedman, José L. Moreno, Mitra Heshmati, Sam A. Golden, Pamela Kennedy, Nagahide Takahashi et al. · 2012 · Nature Neuroscience
52. Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia
    Todd Lencz, Thomas Morgan, M Athanasiou, B. Dain, Carol R. Reed, John Michael Kane, Raju Kucherlapati, Anil K. Malhotra · 2002 · Molecular Psychiatry
53. Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
    Peng Li, Gretchen L. Snyder, Kimberly E. Vanover · 2016 · Current Topics in Medicinal Chemistry
54. The science of well-being: an integrated approach to mental health and its disorders.
    Claude Robert Cloninger · 2006 · PubMed
55. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics
    Christoph Ulrich Correll · 2010 · European Psychiatry
56. A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated With Initiation of Atypical Antipsychotic Therapy in Children and Adolescents
    David J. Klein, Elizabeth M. Cottingham, Michael T. Sorter, BRUCE A. BARTON, John A. Morrison · 2006 · American Journal of Psychiatry
57. Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic Disorders
    Mario Álvarez‐Jiménez, César González‐Blanch, Benedicto Crespo‐Facorro, Sarah Elisabeth Hetrick, José Manuel Rodríguez-Sánchez, Rocío Pérez‐Iglesias, José Luis Vázquez‐Barquero · 2008 · CNS Drugs
58. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
    Chouinard, Guy, Samaha, Anne-Noël, Chouinard, Virginie-Anne, Peretti, Charles-Siegfried, Kanahara, Nobuhisa, Takase, Masayuki, Iyo, Masaomi · 2017 · Psychotherapy and Psychosomatics
59. Personalized medicine in psychiatry: problems and promises
    Ozomaro, Uzoezi, Wahlestedt, Claes, Nemeroff, Charles B · 2013 · BMC Medicine
60. Introduction: Methods, Commentary, and Summary
    Michael H. Allen, Glenn W. Currier, Daniel P. Carpenter, RUTH W. ROSS, John P. Docherty · 2005 · Journal of Psychiatric Practice
61. Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences
    Marco Carli, Shivakumar Kolachalam, Biancamaria Longoni, Anna Maria Pintaudi, Marco Baldini, Stefano Aringhieri, Irene Fasciani, Paolo Annibale, Roberto Maggio, Marco Scarselli · 2021 · Pharmaceuticals
62. Metabolic side effects of antipsychotic medication
    Alexander Tschoner, Julia Engl, Markus Wolfgang Laimer, Susanne Kaser, Maria A. Rettenbacher, W. Wolfgang Fleischhacker, Josef R. Patsch, Christoph F. Ebenbichler · 2007 · International Journal of Clinical Practice
63. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial
    Anthony P. Morrison, Douglas Turkington, Melissa Pyle, Helen M. Spencer, Alison Brabban, Graham Dunn, Tom Christodoulides, Robert E. J. Dudley, Nicola Chapman, Pauline Callcott et al. · 2014 · The Lancet
64. Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: a cluster-randomised controlled trial
    Ballard, Clive, Corbett, Anne, Orrell, Martin, Williams, Gareth, Moniz-Cook, Esme, Romeo, Renee, Woods, Bob, Garrod, Lucy, Testad, Ingelin, Woodward-Carlton, Barbara et al. · 2018 · PLOS Medicine
65. ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
    Jeffrey Alan Lieberman, Robert E. Davis, Christoph Ulrich Correll, DONALD C. GOFF, John Michael Kane, Carol A. Tamminga, Sharon L. Mates, Kimberly E. Vanover · 2015 · Biological Psychiatry
66. Extrapyramidal side-effects of antipsychotics in a randomised trial
    Del D. Miller, Stanley N. Caroff, Sonia Thomas, Robert Alan Rosenheck, Joseph P. McEvoy, Bruce L. Saltz, Silvana Riggio, Miranda Chakos, Marvin S. Swartz, Richard S.E. Keefe et al. · 2008 · The British Journal of Psychiatry
67. Metabolomic Mapping of Atypical Antipsychotic Effects in Schizophrenia
    Kaddurah-Daouk, R, McEvoy, J, Baillie, R A, Lee, D, Yao, J K, Doraiswamy, P M, Krishnan, K R R · 2007 · Molecular Psychiatry
68. QTc Prolongation by Psychotropic Drugs and the Risk of Torsade de Pointes
    Katharina Wenzel‐Seifert, Markus Wittmann, Ekkehard Haen · 2011 · Deutsches Ärzteblatt international
69. Quetiapine versus other atypical antipsychotics for schizophrenia
    Katja Komossa, Christine Rummel‐Kluge, Franziska Schmid, Heike Hunger, Sandra Schwarz, Manit Srisurapanont, Werner Kissling, Stefan Leucht · 2010 · Cochrane Database of Systematic Reviews
70. Revolution Stalled
    Hyman, Steven E. · 2012 · Science Translational Medicine
71. Mortality Risk in Patients With Dementia Treated With Antipsychotics Versus Other Psychiatric Medications
    Kales, Helen C., Valenstein, Marcia, Kim, H. Myra, McCarthy, John F., Ganoczy, Dara, Cunningham, Francesca, Blow, Frederic C. · 2007 · American Journal of Psychiatry
72. Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia
    Mohamed, S., Rosenheck, R., McEvoy, J., Swartz, M., Stroup, S., Lieberman, J. A. · 2009 · Schizophrenia Bulletin
73. Clinical predictors of therapeutic response to antipsychotics in schizophrenia
    Carbon, Maren, Correll, Christoph U. · 2014 · Dialogues in Clinical Neuroscience
74. What’s in a name? Compliance, adherence and concordance in chronic psychiatric disorders
    Chakrabarti, Subho · 2014 · World Journal of Psychiatry
75. A Double-Blind Comparison of Citalopram and Risperidone for the Treatment of Behavioral and Psychotic Symptoms Associated With Dementia
    Pollock, Bruce G., Mulsant, Benoit H., Rosen, Jules, Mazumdar, Sati, Blakesley, Richard E., Houck, Patricia R., Huber, Kimberly A. · 2007 · The American Journal of Geriatric Psychiatry
76. Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents
    Lawrence A. Maayan, Christoph Ulrich Correll · 2011 · Journal of Child and Adolescent Psychopharmacology
77. Relationships Among Subjective and Objective Measures of Adherence to Oral Antipsychotic Medications
    Dawn I. Velligan, Mei Wang, Pamela M. Diamond, David C. Glahn, Desiree Castillo, Scott Bendle, Y. W. Francis Lam, Larry Ereshefsky, Alexander L. Miller · 2007 · Psychiatric Services
78. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta‐analysis and meta‐regression analysis
    Britta Galling, Alexandra Roldán, Katsuhiko Hagi, Liz Rietschel, Frozan Walyzada, Wei Zheng, Xiao‐Lan Cao, Yu‐Tao Xiang, Mathias Zink, John Michael Kane et al. · 2017 · World Psychiatry
79. Paliperidone for schizophrenia
    Christian R. Dolder, Michael Nelson, Zachariah M. Deyo · 2008 · American Journal of Health-System Pharmacy
80. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge
    Steven C. Marcus, Jacqueline Zummo, Amy R. Pettit, Jeffrey J. Stoddard, Jalpa A. Doshi · 2015 · Journal of Managed Care & Specialty Pharmacy
81. Long-Term Efficacy and Safety of Iloperidone
    John Michael Kane, John Lauriello, EUGENE M. LASKA, Michael E. Di Marino, Curt D. Wolfgang · 2008 · Journal of Clinical Psychopharmacology
82. Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study
    Herbert Y. Meltzer, Josephine B. Cucchiaro, Robert Silva, Masaaki Ogasa, Debra Phillips, Jane Xu, Amir H Kalali, Edward Ernest Schweizer, Andrei Pikalov, Antony D Loebel · 2011 · American Journal of Psychiatry
83. The metabolic syndrome and schizophrenia
    Jonathan M. Meyer, Stephen M. Stahl · 2008 · Acta Psychiatrica Scandinavica
84. GABA Neuron Alterations, Cortical Circuit Dysfunction and Cognitive Deficits in Schizophrenia
    Guillermo González‐Burgos, Kenneth N. Fish, David A. Lewis · 2011 · Neural Plasticity
85. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study
    Michael Davidson, Robin Alexander Emsley, Michelle L. Kramer, Lisa Ford, Guohua Pan, Pilar Lim, Mariëlle Eerdekens · 2007 · Schizophrenia Research
86. EPA guidance on assessment of negative symptoms in schizophrenia
    Silvana Galderisi, Armida Mucci, Sonia Dollfus, Merete Nordentoft, Peter Falkai, Stefan Kaiser, Giulia Maria Giordano, Anaïs Vandevelde, Mette Ødegaard Nielsen, Louise Birkedal Glenthøj et al. · 2021 · European Psychiatry
87. Antipsychotic Therapy During Early and Late Pregnancy. A Systematic Review
    Salvatore Gentile · 2008 · Schizophrenia Bulletin
88. World Journal of Pharmaceutical Sciences
    2021 · World Journal of Pharmaceutical Sciences
89. Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia
    Gagan Fervaha, George Foussias, Ofer Agid, Gary J. Remington · 2014 · Acta Psychiatrica Scandinavica
90. Stigma Resistance in Patients With Schizophrenia
    Ingrid Sibitz, Annemarie Unger, Andreas Woppmann, Thomas Zidek, Michaela Amering · 2009 · Schizophrenia Bulletin
91. Community Violence Perpetration and Victimization Among Adults With Mental Illnesses
    Sarah L. Desmarais, Richard A. Van Dorn, Kiersten L. Johnson, Kevin J. Grimm, Kevin S. Douglas, Marvin S. Swartz · 2014 · American Journal of Public Health
92. Oscillations and Neuronal Dynamics in Schizophrenia: The Search for Basic Symptoms and Translational Opportunities
    Uhlhaas, Peter J., Singer, Wolf · 2015 · Biological Psychiatry
93. Acute Effects of Atypical Antipsychotics on Whole-Body Insulin Resistance in Rats: Implications for Adverse Metabolic Effects
    Karen L. Houseknecht, Alan S. Robertson, William J. Zavadoski, E. Michael Gibbs, David E. Johnson, Hans Rollema · 2006 · Neuropsychopharmacology
94. Ziprasidone versus other atypical antipsychotics for schizophrenia
    Katja Komossa, Christine Rummel‐Kluge, Heike Hunger, Sandra Schwarz, Paranthaman Sethupathi Bhoopathi, Werner Kissling, Stefan Leucht · 2009 · Cochrane Database of Systematic Reviews
95. Impact of FDA Black Box Advisory on Antipsychotic Medication Use
    Earl Ray Dorsey · 2010 · Archives of Internal Medicine
96. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies
    David A. Lewis, Robert A. Sweet · 2009 · Journal of Clinical Investigation
97. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation
    Stefan Leucht, John M. Davis, Rolf R. Engel, Werner Kissling, John Michael Kane · 2008 · Acta Psychiatrica Scandinavica
98. Side effects of atypical antipsychotics: a brief overview
    Alp Üçok, Wolfgang Gäebel · 2008 · World Psychiatry
99. How evidence‐based medicine is failing due to biased trials and selective publication
    Susanna Every‐Palmer, Jeremy Howick · 2014 · Journal of Evaluation in Clinical Practice
100. Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia
     Kimberly E. Vanover, Robert E. Davis, Yun Zhou, Weiguo Ye, James Robert Brašić, Lorena Gapasin, Jelena Saillard, Michal Weingart, Robert E. Litman, Sharon L. Mates et al. · 2018 · Neuropsychopharmacology